Table 3 Between-group comparisons at Week 16: effects of 8-weeks TETA treatment on cardiac function in diabetic cardiomyopathy

Body-weight (g)

489 (466–511)

313 (283–344) ^a

346 (323–368) ^a

< 0.0001

Blood glucose (mM)

4.7 (4.4-5.1)

28.8 (27.2-30.4) ^a

28.0 (25.7-30.4) ^a

< 0.0001

Heart Rate (bpm)

396 (384–408)

317 (306–328) ^a

336 (326–346) ^{a, b}

< 0.0001

LVM (mg)

785 (744–826)

732 (698–767)

737 (688–767)

0.049

LVM/BW (mg/g)

1.61(1.51-1.71)

2.38 (2.18-2.57) ^a

2.12 (1.98-2.27) ^{a, b}

< 0.0001

CO (ml/min)

222 (213–232)

130 (123–136) ^a

159 (151–167) ^{a, b}

< 0.0001

CO/LVM (ml/min.mg)

0.28 (0.26-0.30)

0.18 (0.17-0.19) ^a

0.22 (0.21-0.23) ^{a, b}

< 0.0001

LVEF (%)

72.9 (70.7-75.1)

62.6 (60.6-64.6) ^a

71.1 (68.8-73.4) ^b

< 0.0001

LVEDV (μl)

770 (753–788)

656 (628–683) ^a

666 (644–687) ^a

< 0.0001

LVEDV/LVM (μl/mg)

0.99 (0.94-1.03)

0.90 (0.85-0.95) ^a

0.92 (0.87-0.97)

0.030

LVESV (μl)

209 (192–225)

246 (229–262) ^a

193 (177–209) ^b

< 0.0001

LVESV/LVM (μl/mg)

0.27 (0.25-0.29)

0.37 (0.35-0.39) ^a

0.29 (0.27-0.31) ^{a, b}

< 0.0001

Stroke Vol (μl)

562 (540–585)

410 (388–433) ^a

473 (452–495) ^b

< 0.0001

Stroke Vol/LVM (μl/mg)

0.72 (0.68-0.76)

0.56 (0.53-0.59) ^a

0.65 (0.62-0.69) ^{a, b}

< 0.0001